Key Highlights

  • Net loss for the third quarter of 2026 was $9.9 million, or $0.68 per share, compared with $6.5 million in the second quarter.
  • Cash, cash equivalents and marketable securities totaled $174.2 million as of September 30, 2026.
  • STX-1150, an epigenetic silencing therapy targeting PCSK9, is in a Phase 1 trial.
  • The Sanofi collaboration was expanded to include the epigenetic silencing technology.

Scribe Therapeutics Inc. (NASDAQ:SCTX) reported financial results for the third quarter ended September 30, 2026, and provided recent corporate and pipeline updates on November 12, 2026. The Alameda, California clinical-stage company develops in vivo CRISPR technologies aimed at cardiometabolic diseases. The quarter followed an upsized initial public offering and an expansion of its collaboration with Sanofi. Its lead clinical program, STX-1150, is in a Phase 1 trial.

Pipeline and STX-1150 Program

STX-1150 is an in vivo epigenetic silencing therapy for lowering low-density lipoprotein cholesterol. It uses Scribe's Epigenetic Long-term X Repressor technology to silence PCSK9, a target the company describes as genetically and clinically validated. The company says STX-1150 is designed to address limitations of current LDL-lowering therapies, which it said are affected by poor persistence and adherence.

Scribe said the program is in an ongoing Phase 1 trial. The release does not provide clinical data from that trial, and the company said it presented additional research on its cardiovascular pipeline and its epigenetic silencing and gene-editing technologies during the quarter.

Collaboration and Capital Markets Activity

Scribe said it completed an upsized IPO that added public healthcare investors to its Shareholder base and broadened analyst coverage. It also expanded its collaboration with Sanofi to include the epigenetic silencing technology, a step Chief Executive Benjamin Oakes described as strengthening the company's foundation.

The company's cash, cash equivalents and marketable securities totaled $174.2 million at September 30, 2026. Scribe said that balance provides funding into the first half of 2029. The release does not detail the size of the Sanofi payments or the milestones in the expanded collaboration.

Quarterly Financial Results

For the three months ended September 30, 2026, Scribe reported a net loss of $9.9 million, or $0.68 per basic and diluted share, compared with a net loss of $6.5 million in the second quarter of 2026. The company's release does not give a year-over-year comparison in its headline section.

The sequential increase in the loss reflects the operating costs of the period, which the company did not describe in detail in its summary. Readers can refer to the full financial statements for the breakdown of research and administrative expenses.

Final Word

The third quarter shows Scribe completing its IPO, broadening its Sanofi collaboration and advancing STX-1150 in Phase 1, while its net loss rose from the prior quarter. The cash balance of $174.2 million is expected to fund the company into 2029. The clinical results from the STX-1150 trial will be the key indicator of whether the epigenetic silencing approach can be developed further.